| Literature DB >> 30629685 |
Mona M Hashem1, Maha M Salama1,2, Faten F Mohammed3, Adel F Tohamy4,5, Kadriya S El Deeb1.
Abstract
Liver diseases are life-threatening and need urgent medical treatments. Conventional treatment is expensive and toxic, so the urge for nutraceutical hepatoprotective agents is crucial. This study is considered the first metabolic profile of Aeschynomene elaphroxylon (Guill. & Perr.) extracts of; flowers, leaves & bark adopting UPLC-Orbitrap HRMS analysis to determine their bioactive metabolites, and it was designed to investigate the potential hepatoprotective activity of A. elaphroxylon flowers and bark extracts against CCl4-induced hepatic fibrosis in rats. Forty-nine compounds of various classes were detected in the three extracts, with triterpenoid saponins as the major detected metabolite. Flowers and bark extracts presented similar chemical profile while leaves extract was quite different. The antioxidant activities of the flowers, leaves & bark extracts were measured by in vitro assays as Fe+3 reducing antioxidant power and Oxygen radical absorbance capacity. It revealed that flowers and bark extracts had relatively high antioxidant activity as compared to leaves extract. Based on the metabolic profile and in vitro antioxidant activity, flowers and bark ethanolic extracts were chosen for alleviation of hepatotoxicity induced by CCl4 in rats. The hepatoprotective activity was studied through measuring hepatotoxicity biomarkers in serum (ALT, AST, and Albumin). Liver tissues were examined histopathologically and their homogenates were used in determining the intracellular levels of oxidative stress biomarkers (MDA, GSH), inflammatory markers (TNF-α). Flowers and bark ethanolic extracts exerted a significant hepatoprotective effect through reduction in the activities of ALT, AST and Albumin, the tested extracts reduced oxidative stress by increasing GSH content and reducing the MDA level. Furthermore, the extracts decreased levels of pro-inflammatory TNF-α. Moreover, the present study revealed the potentiality of A. elaphroxylon in ameliorating the CCl4-induced hepatic fibrosis in rats. In this aspect, A. elaphroxylon can be used with other agents as a complementary drug.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30629685 PMCID: PMC6328266 DOI: 10.1371/journal.pone.0210576
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Metabolites identified in A. elaphroxylon (Guill. & Perr.) flowers, bark and leaves extracts using UPLC- Orbitrap HRMS.
| Peak no. | m/z | Mode | tR (min) | λmax (nm) | Deprotonated moleclar Formula | Error | MS/MS− | Identification | Plant organ | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| flower | bark | leaf | |||||||||
| 1 | 191.0556 | N | 0.66 | 249 | C7H11O6 | 0.635 | 173,127,111 | Quinic acid | + | _ | _ |
| 2 | 153.0192 | N | 1.94 | 262, | C7H5O4 | 5.5 | 109 | Protocatechuic acid | + | _ | _ |
| 3 | 315.0688 | N | 2.52 | Nd | C13H15O9 | 6.5 | 169, 151 | Gallic acid deoxysugar | + | _ | _ |
| 4 | 255.0500 | N | 4.70 | Nd | C11H11O7 | 0.51 | 237,195 | Unidentified | + | + | - |
| 5 | 337.0910 | N | 6.67 | Nd | C16H17O8 | 2.088 | 191,163,173 | 5 | + | _ | + |
| 6 | 353.0866 | N,P | 8.81 | 280 | C15H17O8 | 0.194 | 191,179 | Chlorogenic acid | _ | _ | + |
| 7 | 325.0916 | N | 8.91 | Nd | C11H11O6 | 163, 145,119 | + | _ | _ | ||
| 8 | 443.1914 | N | 8.97 | Nd | C21H31O10 | 0.437 | 347,283,248 | Unidentified | + | - | - |
| 9 | 239.0554 | N | 9.21 | Nd | C16H19O9 | 1.78 | 221,195,179, 149 | Caffeic acid derivative | + | + | _ |
| 10 | 355.1026 | N | 9.55 | 215, | C9H7O3 | 0.680 | 217,193.175 | feruloyl | _ | _ | + |
| 11 | 163.0399 | N | 9.91 | 216, | C11H11O5 | 6.068 | 119 | _ | _ | + | |
| 12 | 431.1907 | N | 9.82 | 282 | C20H31O10 | 0.206 | 385,225,179 | Unidentified | _ | + | _ |
| 13 | 223.0606 | N | 10.22 | Nd | C18H15O8 | 0.540 | 205,179,163, | Sinapinic acid | _ | + | _ |
| 14 | 359.0760 | N | 10.68 | 215, | C15H17O8 | 0.261 | 161,179,197 | Rosmarinic acid | _ | _ | + |
| 15 | 321.0596 | N | 8.63 | Nd | C15H13O8 | 1.23 | 277,233,284 | Leucodelphinidin | + | _ | _ |
| 16 | 577.133 | N, P | 9.4 | 282, | C30H25O12 | 0.767 | 289,407,425, | Procyanidin dimmer B1 | + | + | _ |
| 17 | 289.0710 | N, P | 9.71 | 282, | C15H13O6 | 1.85 | 245,205, 179 | (+)- Catechin (A) | + | + | _ |
| 18 | 865.1967 | N | 9.84 | 282, | C54H37O18 | 1.64 | 847,695,577, | Procyanidin trimmer | _ | + | _ |
| 19 | 595.1641 | N, P | 9.36 | 290, | C27H31O15 | 0.039 | 577,505, 475,329,359 | Dihydrokaempferol - | + | _ | _ |
| 20 | 609.144 | N | 9.70 | 282, | C27H29O16 | 0.084 | 447,285 | Kaempferol | + | _ | + |
| 21 | 579.1703 | N, P | 9.91 | 284, | C27H31O14 | 0.314 | 561,489.459, | Naringenin - | + | + | _ |
| 22 | 625.1394 | N, P | 9.93 | 325 | C27H29O17 | 0.633 | 607,581,505 | Quercetin | _ | _ | + |
| 23 | 331.0928 | N, P | 9.99 | 282 | C21H15O4 | 10.82 | 313,287,269 | Unidentified | + | _ | _ |
| 24 | 593.149 | N | 10.13 | 271, | C27H29O15 | 0.534 | 447, 431,285 | Kaempferol-3 | + | _ | _ |
| 25 | 563.139 | N, P | 10.21 | 274, | C26H27O14 | 0.234 | 447, 431,285 | Kaemferol | + | _ | _ |
| 26 | 463.087 | N | 10.33 | 265, | C21H19O12 | 0.189 | 301 | Quercetin-3 | _ | _ | + |
| 27 | 577.156 | N, P | 10.34 | 267, | C27H29O14 | 1.128 | 431,417, 285 | kaempferol-3,7 | + | + | _ |
| 28 | 447.092 | N | 10.48 | 281, | C21H19O11 | 0.139 | 431, 285 | Kaempferol | + | + | + |
| 29 | 417.081 | N | 10.68 | 281 | C20H17O10 | 0.703 | 285 | Kaempferol | + | _ | _ |
| 30 | 655.3054 | N | 10.72 | 216, | C43H43O6 | 0.065 | 632 | Unidentified | _ | + | _ |
| 31 | 431.097 | N | 10.81 | 282 | C21H19O10 | 0.031 | 285 | Kaemferol | + | _ | _ |
| 32 | 379.1657 | N, P | 10.84 | 215, | C27H23O2 | 9.59 | 259 | Unidentified | + | _ | _ |
| 33 | 467.2428 | N | 10.90 | 220 | C28H35O6 | 0.032 | 452,449,423 | Unidentified | _ | _ | + |
| 34 | 725.206 | N, P | 10.98 | 284 | C36H37O16 | 1.395 | 707,635,605, 579, 563, 272 | Naringenin | + | _ | _ |
| 35 | 582.2598 | N, P | 11.1 | 292 | C28H40O12N | 9.14 | 462,436, 342,372 | Quercetin | + | _ | _ |
| 36 | 531.2584 | N | 11.21 | 221 | C29H39O9 | 0.714 | 513,485,467 | Unidentified | _ | _ | _ |
| 37 | 957.5037 | N, P | 11.17 | 220, 281 | C48H77O19 | 1.636 | 939, 895, 811, 767, 631,473 | Soyasaponin V | + | + | _ |
| 38 | 955.4880 | N | 11.51 | 221, 282 | C48H75O19 | 1.666 | 937, 911, 893, 809, 539, 471 | deoxyhexose -hexose-hexuronic acid Hederagenin | _ | + | _ |
| 39 | 911.4979 | N | 11.80 | 222 | C47H76O18 | 1.609 | 893,849,765, 615, 571,457 | Soyasaponin II | + | _ | _ |
| 40 | 941.5081 | N, P | 11.85 | 222 | C48H77O18 | 2.466 | 923, 879, 795, 751, 633, 457 | Soyasaponin I | + | + | _ |
| 41 | 925.5143 | N | 11.94 | 222 | C48H77O17 | 1.283 | 907, 863,779, 599.509,439 | Unknown teriterpenoid saponin | + | _ | _ |
| 42 | 795.4508 | N, P | 11.97 | 222 | C42H67O14 | 1.723 | 733, 633, 525, 457 | Soyasaponin III | _ | + | _ |
| 43 | 939.4924 | N, P | 12.1 | 222 | C48H75O18 | 2.45 | 921, 877, 793, 613, 523, 455 | Pisumsaponin II | + | + | _ |
| 44 | 895.5026 | N, P | 12.17 | 222 | C47H75O16 | 2.538 | 877, 833, 749, 731, 599, 439 | Unknown teriterpenoid saponin | + | _ | _ |
| 45 | 1067.539 | N, P | 12.17 | 222 | C54H85O21 | 0.182 | 1049, 921, 759, 741, 651, 457 | Soyasaponin | _ | + | _ |
| 46 | 923.4980 | N | 12.24 | 222 | C48H75O17 | 1.978 | 905, 861, 777, 597, 507, 437 | Unknown teriterpenoid saponin | + | _ | _ |
| 47 | 633.3981 | N | 12.29 | 222 | C36H57O9 | 2.494 | 615, 457 | Hexuronic acid Soyasapogenol B | _ | + | _ |
| 48 | 921.4824 | N, P | 12.30 | 222 | C48H73O17 | 1.747 | 741, 457 | Soyasaponin | _ | + | _ |
| 49 | 327.2167 | N | 11.52 | 220, | C18H31O5 | 0.058 | 291, 229, 211,183 | Trihydroxy-octadecadienoic acid (C18:2) | + | + | + |
| 50 | 329.2320 | N | 11.67 | 220, | C18H33O5 | 0.787 | Trihydroxy-octadecaenoic acid (C18:1) | + | + | + | |
| 51 | 287.2215 | N | 11.74 | 218 | C16H31O4 | 0.089 | 311,229,211 | Dihydroxy-hexadecanoic acid (C16:0) | + | _ | _ |
| 52 | 609.2660 | N | 11.77 | 222 | C41H37O5 | 429,293 | Unidentified | _ | _ | + | |
| 53 | 309.2065 | N | 11.94 | 222 | C18H29O4 | 1.630 | 248, 174, 161 | Dihydroxy-octadecatrienoic acid | _ | _ | + |
| 54 | 307.1909 | N | 11.97 | 222 | C18H27O4 | 1.739 | 291,251,171 | hydroxy-oxooctadeca-trienoic acid | _ | _ | + |
| 55 | 653.2643 | N | 12.06 | 222 | C28H45O17 | 1.203 | 607,565 | Unidentified | _ | _ | + |
| 56 | 311.222 | N | 12.28 | 223 | C18H31O4 | 1.459 | 289,235,185 | Octadec-2-enedioic acid (C18:1) | + | + | _ |
| 57 | 695.2748 | N | 12.41 | 222 | C30H47O18 | 1.224 | 607,565 | Unidentified | _ | _ | + |
| 58 | 313.237 | N | 12.49 | 223 | C18H33O4 | 1.449 | 293,275,223 | Octadecanedioic acid (C18:0) | + | + | _ |
| 59 | 721.3631 | N | 12.50 | 222 | C34H57O16 | 1.320 | 675 | Unidentified | _ | _ | + |
| 61 | 293.2116 | N | 12.92 | 220 | C18H29O3 | 0.001 | 295,277,201 | Hydroxy-octadecatrienoic acid (C18:3) | + | + | + |
| 62 | 295.2268 | N | 13.15 | 220 | C18H31O3 | 0.334 | 275,235,211, | Hydroxy-octadecadienoic acid (C18:2) | + | + | + |
| 63 | 743.3468 | N | 13.53 | 222 | C36H55O16 | 2.155 | 697,579,529 | Unidentified | _ | _ | + |
| 64 | 555.2826 | N | 13.63 | 224 | C28H43O11 | 5.351 | 556.299.225 | Unidentified | _ | _ | + |
| 65 | 271.2273 | N | 14.23 | 220 | C16H31O3 | 0.148 | 277,195,171 | Hydroxy-hexadecanoic acid (C16:0) | + | _ | _ |
| 66 | 455.3518 | N | 15.69 | 224 | C30H47O3 | 1.49 | 437, 411,393 | Oleanolic acid | + | _ | _ |
| 67 | 341.2685 | N | 17.68 | 225 | C20H37O4 | 0.21 | 313,269 | Eicosanedioic acid | + | + | _ |
Nd. Not defined, N. negative, P. positive
Fig 1TIC chromatograms of UPLC-Orbitrap-HRMS of Numbers refer to identified compounds listed in Table 1.
Fig 2TIC chromatograms of UPLC-Orbitrap-HRMS of Numbers refer to identified compounds listed in Table 1.
Fig 3TIC chromatograms of UPLC-Orbitrap-HRMS of Numbers refer to identified compounds listed in Table 1.
Effect of A. elaphroxylon flowers and bark extracts and silymarin on liver functions, TNF-α, oxidative stress Markers against CCL4-induced hepatic damage.
| Normal | CCl4 | Si + CCl4 | F-Et +CCl4 | B-Et +CCl4 (200mg /kg/d) | |
|---|---|---|---|---|---|
| 30.52±2.08( | 79.26±9.59( | 37.35±8.58( | 43.23±3.65( | 41.31±6.01( | |
| 41.23±1.31( | 78.81±0.72( | 47.81±0.78( | 54.45±0.57( | 51.46±0.55( | |
| 3.46±0.057( | 2.35±0.067( | 3.36±0.057( | 3.15±0.11( | 3.21 ± 0.46( | |
| 2.66 ± 0.23( | 1.12 ± 0.15( | 2.58 ± 0.14( | 2.12 ± 0.04( | 2.32±0.156( | |
| 6.31 ± 0.522( | 12.44 ± 1.311( | 8.72 ± 0.847( | 8.41± 0.454( | 7.40±0.771( | |
| 0.30±0.029( | 0.63±0.031( | 0.35±0.034( | 0.43±0.037( | 0.46±0.035( |
Si = silymarin, F-Et = Ethanol (70%) extract of flowers, B-Et = Ethanol (70%) extract of bark.
Each value expressed as mean ± SEM, (n = 5).
(a) Significantly different from CCl4 group at p < 0.05.
(b)Significantly different from normal group at p < 0.05.
Statistical analysis was performed using one-way ANOVA followed by Tukey -Kramer as a post hoc test.
Histopathological lesions scoring in different treated groups.
| Group | Grade of | Connective tissue intensity | α- SMA expression | Caspase-3 expression |
|---|---|---|---|---|
| CCl4 | 3.18 ± 0.88 (c) | 30.04 ± 24.31(b) | 11.48 ± 1.93 (b) | 18.88 ± 3.52 (b) |
| Si+ CCl4 | 1.46 ± 0.63 (ab) | 9.29± 1.42 (a) | 2.83 ± 1.17 (a) | 9.95 ± 1.67 (a) |
| F-Et+ CCl4 | 1.51 ± 0.70 (b) | 10.21 ± 10.08 (a) | 2.96 ± 1.21 (a) | 11.81 ± 1.29 (a) |
| B-Et + CCl4 | 1.16 ± 0.65 (a) | 6.37 ± 2.10 (a) | 2.72 ± 0.57 (a) | 8.05 ± 1.39 (a) |
Each value expressed as mean ± SEM, (n = 5).
Different letters in the same column are significantly different (p ≤ 0.05).
Fig 4Liver histological sections (H&E) of CCl4-intoxicated rat.
(a) disruption of hepatic architecture (X200). (b) Mononuclear cell infiltration between hepatic lobules (arrow) consisted mainly of macrophages associated with macrovesicular steatosis of hepatocytes (X200). (c) Apoptosis of individual hepatocytes (arrow) with appearance of mitotic figures(arrow head) (X400). (d) Hepatocytes with various figures of mitosis (arrow) (X400). (e) Oval cell proliferation in the portal area and extending into hepatic lobule (arrow) (X400). (f) Hepatocytes with cytomegaly, binucleation and karyomegaly (arrow) (X400).
Fig 5Liver histological sections (H&E).
(a) Sylimarin+CCl4 showing mild oval cell proliferation in portal area with few mononuclear cell infiltration (X200). (b) kupffer cell activation with individual mitosis of hepatocytes (arrow) and binucleated hepatocytes(X400). (c) F-Et + CCl4 showing mild disruption of hepatic lobular architecture with fibrous septa separating hepatic lobules with vacuolization of hepatocellular cytoplasm(X200). (d) mononuclear cell infiltration in the portal area and individual mitosis of hepatocytes (arrow) (X400). (e) B-Et +CCl4 showing diffuse vacuolization of hepatocytes with maintaining of lobular strucure(X200). (f) mild mononuclear cell aggreation,oval cell proliferation with newly formed bile ductules (arrow) (X400).
Fig 6Liver histological sections stained with Masson`s Trichrom.
(a) CCl4-intoxiated group showing dense bridging fibrosis with pesudolobules formation(X200). (b) sylimarin+ CCl4 group showing occasional bridging fibrosis (X200). (c) F-Et+CCl4 showing bridging fibrosis (X100). (d) B-Et +CCl4 group showing fine fibrous septa extending from portal are into hepatic lobules (X100).
Fig 7Immunohistochemical stainig of liver section stained with alpha smooth muscle actin antibody(α-SMA) (X200).
(a) CCl4 intoxicated group showing dense brown expression of α-SMA in between hepatic lobules and into hepatic lobules between hepatocytes. (b) sylimarin+CCl4 group showing fine expression of α-SMA in portal area and in between hepatic lobules. (c) F-Et+ CCl4 showing more expression of α-SMA into hepatic lobules (X100). (d) B-Et +CCl4 group showing faint expression of α-SMA between hepatic lobules.
Fig 8Immunohistochemical stainig of liver section stained with caspase-3 antibody(X400).
(a) CCl4 intoxicated group showing diffuse and dense cytoplasmic and nuclear caspase-3 expression in hepatocytes. (b) Si+ CCl4 group showing focal and faint cytoplamic and nuclear caspase-3 expression in heaptocytes. (c) F-Et+ CCl4 group showing focal and less dense cytoplamic and nuclear caspase-3 expression in heaptocytes. (d) B-Et + CCl4 group showing individual hepatocytes cytoplamic and nuclear caspase-3 expression.